OBJECTIVES: We sought to determine the effects of PCSK9 variants on plasma low-density lipoprotein cholesterol (LDL-C) levels, severity of coronary atherosclerosis, and response to statin therapy in the Lipoprotein Coronary Atherosclerosis Study (LCAS) population. BACKGROUND: Mutations in PCSK9 cause autosomal-dominant hypercholesterolemia. We hypothesized that PCSK9 variants could affect plasma LDL-C in individuals with polygenic hypercholesterolemia. METHODS: We sequenced all 12 exons and boundaries to detect novel polymorphisms, and genotyped 372 subjects in LCAS and 319 subjects in a second independent population for six polymorphisms, including novel leucine repeats, by fluorescently tagged markers. We reconstructed haplotypes using a Bayesian algorithm. RESULTS: Permutation test results showed statistically significant differences in global haplotype distribution among the tertiles of LDL-C (odds ratio [OR]: 2.36, 95% confidence interval [CI]: 1.90 to 4.32, p = 0.005) and minimum lumen diameter of coronary lesions (OR: 1.83, 95% CI: 1.01 to 3.55, p = 0.045). Regression analysis identified haplotype 3 as an independent determinant of LDL-C levels (adjusted R2 = 2.2%, F = 9.37, p = 0.002). Haplotype structure analysis identified E670G as the determinant variant, exerting a dose effect (GG > EG > EE) and accounting for 3.5% of plasma LDL-C variability (F = 14.6, p < 0.001). Plasma total cholesterol, apolipoprotein B, and lipoprotein (a) levels were also associated with the E670G variant. Distributions of the E670G genotypes in an independent normolipidemic and the hyperlipidemic LCAS populations were significantly different (F = 7.2, p = 0.027). No significant treatment-by-genotype interactions were detected. The false positive report probability was between 2% and 8%. CONCLUSIONS: Haplotype 3 encompassing the E670G variant is an independent determinant of plasma LDL-C levels and the severity of coronary atherosclerosis.
OBJECTIVES: We sought to determine the effects of PCSK9 variants on plasma low-density lipoprotein cholesterol (LDL-C) levels, severity of coronary atherosclerosis, and response to statin therapy in the Lipoprotein Coronary Atherosclerosis Study (LCAS) population. BACKGROUND: Mutations in PCSK9 cause autosomal-dominant hypercholesterolemia. We hypothesized that PCSK9 variants could affect plasma LDL-C in individuals with polygenic hypercholesterolemia. METHODS: We sequenced all 12 exons and boundaries to detect novel polymorphisms, and genotyped 372 subjects in LCAS and 319 subjects in a second independent population for six polymorphisms, including novel leucine repeats, by fluorescently tagged markers. We reconstructed haplotypes using a Bayesian algorithm. RESULTS: Permutation test results showed statistically significant differences in global haplotype distribution among the tertiles of LDL-C (odds ratio [OR]: 2.36, 95% confidence interval [CI]: 1.90 to 4.32, p = 0.005) and minimum lumen diameter of coronary lesions (OR: 1.83, 95% CI: 1.01 to 3.55, p = 0.045). Regression analysis identified haplotype 3 as an independent determinant of LDL-C levels (adjusted R2 = 2.2%, F = 9.37, p = 0.002). Haplotype structure analysis identified E670G as the determinant variant, exerting a dose effect (GG > EG > EE) and accounting for 3.5% of plasma LDL-C variability (F = 14.6, p < 0.001). Plasma total cholesterol, apolipoprotein B, and lipoprotein (a) levels were also associated with the E670G variant. Distributions of the E670G genotypes in an independent normolipidemic and the hyperlipidemic LCAS populations were significantly different (F = 7.2, p = 0.027). No significant treatment-by-genotype interactions were detected. The false positive report probability was between 2% and 8%. CONCLUSIONS: Haplotype 3 encompassing the E670G variant is an independent determinant of plasma LDL-C levels and the severity of coronary atherosclerosis.
Authors: D Ornish; L W Scherwitz; J H Billings; S E Brown; K L Gould; T A Merritt; S Sparler; W T Armstrong; T A Ports; R L Kirkeeide; C Hogeboom; R J Brand Journal: JAMA Date: 1998-12-16 Impact factor: 56.272
Authors: C M Ballantyne; J A Herd; E A Stein; L L Ferlic; J K Dunn; A M Gotto; A J Marian Journal: J Am Coll Cardiol Date: 2000-11-01 Impact factor: 24.094
Authors: J A Herd; C M Ballantyne; J A Farmer; J J Ferguson; P H Jones; M S West; K L Gould; A M Gotto Journal: Am J Cardiol Date: 1997-08-01 Impact factor: 2.778
Authors: M H Frick; M Syvänne; M S Nieminen; H Kauma; S Majahalme; V Virtanen; Y A Kesäniemi; A Pasternack; M R Taskinen Journal: Circulation Date: 1997-10-07 Impact factor: 29.690
Authors: M Varret; J P Rabès; B Saint-Jore; A Cenarro; J C Marinoni; F Civeira; M Devillers; M Krempf; M Coulon; R Thiart; M J Kotze; H Schmidt; J C Buzzi; G M Kostner; S Bertolini; M Pocovi; A Rosa; M Farnier; M Martinez; C Junien; C Boileau Journal: Am J Hum Genet Date: 1999-05 Impact factor: 11.025
Authors: Ingrid K Kotowski; Alexander Pertsemlidis; Amy Luke; Richard S Cooper; Gloria L Vega; Jonathan C Cohen; Helen H Hobbs Journal: Am J Hum Genet Date: 2006-01-20 Impact factor: 11.025
Authors: Q Feng; W Q Wei; C P Chung; R T Levinson; L Bastarache; J C Denny; C M Stein Journal: Pharmacogenomics J Date: 2016-02-23 Impact factor: 3.550
Authors: Diederik W D Kuster; Adriana Cardenas-Ospina; Lawson Miller; Christoph Liebetrau; Christian Troidl; Holger M Nef; Helge Möllmann; Christian W Hamm; Karen S Pieper; Kenneth W Mahaffey; Neal S Kleiman; Bruno D Stuyvers; Ali J Marian; Sakthivel Sadayappan Journal: Am J Physiol Heart Circ Physiol Date: 2013-12-13 Impact factor: 4.733